Factors for predicting treatment success and severe adverse events of chimeric antigen receptor (CAR) T-cell therapy in relapsed or refractory diffuse large B-cell lymphoma-Reference-Cited by-同舟云学术

Factors for predicting treatment success and severe adverse events of chimeric antigen receptor (CAR) T-cell therapy in relapsed or refractory diffuse large B-cell lymphoma

Published:2023-11-15 Issue:11 Volume:2023 Page:
ISSN:1465-1858
Container-title:Cochrane Database of Systematic Reviews
language:en
Short-container-title:

Author:

Hirsch Caroline¹,Goldkuhle Marius¹,Ernst Moritz¹,Monsef Ina¹,von Tresckow Bastian²³,Skoetz Nicole¹,Kreuzberger Nina¹

Affiliation:

1. Cochrane Haematology, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf; Faculty of Medicine and University Hospital Cologne, University of Cologne; Cologne Germany

2. Department I of Internal Medicine; Faculty of Medicine and University Hospital Cologne, University of Cologne; Cologne Germany

3. Department of Hematology and Stem Cell Transplantation; West German Cancer Center, University Hospital Essen, University of Duisburg-Essen; Essen Germany

Publisher

Wiley

Subject

Pharmacology (medical)

Reference46 articles.

1. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study;Abramson;Lancet,2020

2. Second-line tisagenlecleucel or standard care in aggressive B-cell lymphoma;Bishop;New England Journal of Medicine,2022

3. Assessing and management of neurotoxicity after CAR-T therapy in diffuse large B-Cell lymphoma;Castaneda-Puglianini;Journal of Blood Medicine,2021

4. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification;Cheson;Journal of Clinical Oncology,2014

5. Established search filters may miss studies when identifying randomized controlled trials;Cooper;Journal of Clinical Epidemiology,2019